TIDMSLN

Silence Therapeutics PLC

14 July 2017

Silence CEO, Ali Mortazavi, appointed Chairman of Ultromics

14 July 2017

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that its CEO Ali Mortazavi has been appointed as Non-Executive Chairman of Ultromics with immediate effect. Ultromics is backed by Oxford Sciences Innovation (OSI).

Ali Mortazavi, Chief Executive Officer of Silence Therapeutics, commented:

"I am truly excited to be joining the Board of Ultromics. Artificial Intelligence will increasingly begin to play a bigger role in medicine as well as other sectors. Ultromics plans to use the combination of Man plus machine rather than Man vs machine in medical imaging."

Enquiries:

 
 Silence Therapeutics plc                         Tel: +44 (0)20 3457 
  Ali Mortazavi, Chief Executive Officer           6900 
  David Ellam, Chief Financial Officer 
 
 Media Enquiries:                                 Tel: +44 (0) 20 3727 
  FTI Consulting                                   1000 
  Simon Conway/Brett Pollard/Stephanie Cuthbert

Notes to Editors

About Ultromics

Ultromics is a platform technology that extracts thousands of data points from a single image, then uses machine learning, a form of Artificial Intelligence (AI), to determine which data points are specific to a certain disease. Currently the technology has been applied to echocardiograms to improve the diagnostic accuracy of coronary artery disease from 80% to greater than 95%. Ultromics is powered by one of the world's largest commercially consented image databases and the underlying technology was born out of the University of Oxford. Ultromics was formed in May 2017 after receiving funding from Oxford Sciences Innovation. Visit www.ultromics.com for more information.

About Silence Therapeutics plc

Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAEADXDFEKXEAF

(END) Dow Jones Newswires

July 14, 2017 02:00 ET (06:00 GMT)

Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Silence Therapeutics Charts.
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Silence Therapeutics Charts.